In the TME, Tregs are involved in tumor development and progression by inhibiting antitumor immunity through inhibition of costimulatory signals, interleukin (IL)-2 consumption, secretion of inhibitory cytokines, metabolic modulation of tryptophan and adenosine, and direct killing of effector T cells [22]. This evidence concerns the gene IL2 and neoplasm.